Maddox Pharma Swiss ApS: Financial statements 2025
CVR: 44714922
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Maddox Pharma Swiss ApS (CVR 44714922) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -125,098 and a net result of DKK -140,376. Equity in the 2025 report amounted to DKK -50,962.
- Gross Profit
- DKK -125,098
- Profit/Loss
- DKK -140,376
- Equity
- DKK -50,962
- Total Assets
- DKK 112,072
Official annual report
How creditworthy is Maddox Pharma Swiss ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Maddox Pharma Swiss ApS has published its interim report for the period March 14, 2024 to December 31, 2024.
As of June 18, 2025, Anna Maria Izydorczyk-Spus is registered as director of Maddox Pharma Swiss ApS.
About Maddox Pharma Swiss ApS
Maddox Pharma Swiss ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2024. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Anna Maria Izydorczyk-Spus, Diego Pesciatini and Gesor Ramona Kissling. The company is owned by Maddox Pharma Swiss GmbH. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -125,098 and a net result of DKK -140,376. Equity in the 2025 report amounted to DKK -50,962.